Is It Time To Reassess Elevance Health (ELV) After A 33% One‑Year Share Price Slide

If you are wondering whether Elevance Health's current share price reflects its true worth, this article will walk you through what the numbers actually say.

Recently, the stock has retreated, with returns of a 1.5% decline over 7 days, an 11.0% decline over 30 days, a 19.6% decline year to date, and a 33.1% decline over the past year from a last close of US$284.79.

These moves have arrived alongside ongoing sector attention on large managed care names and investor focus on how insurers are pricing medical costs and membership growth. Broader sentiment around US healthcare policy and reimbursement has also been in the background, shaping how investors are thinking about risk and reward in the group.

Against that backdrop, Elevance Health scores 6 out of 6 on Simply Wall St's valuation checks. This sets up a closer look at how different methods assess fair value, and why an even more complete way of thinking about valuation will matter by the end of this article.

Find out why Elevance Health's -33.1% return over the last year is lagging behind its peers.

Approach 1: Elevance Health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business might be worth by projecting its future cash flows and discounting them back to today to account for risk and the time value of money.

For Elevance Health, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow stands at about US$2.96b. Analyst and extrapolated projections supplied to Simply Wall St show free cash flow estimates such as US$4.97b in 2026 and US$8.29b in 2030, with further extrapolated figures out to 2035, all expressed in US$.

When these projected cash flows are discounted back, the DCF model arrives at an estimated intrinsic value of about US$1,010.17 per share. Compared with the recent share price of US$284.79, this implies the stock is 71.8% undervalued on this measure.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Elevance Health is undervalued by 71.8%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Elevance Health.

Approach 2: Elevance Health Price vs Earnings

For a profitable company, the P/E ratio is a useful shorthand for what investors are currently willing to pay for each dollar of earnings. It distills expectations about future growth and the risk around those earnings into a single number that is easy to compare with other stocks.

Higher growth and lower perceived risk usually support a higher "normal" or "fair" P/E, while slower growth or higher uncertainty tend to justify a lower one. Elevance Health currently trades on a P/E of 11.05x, compared with an average of 22.84x for the wider Healthcare industry and a peer group average of 20.74x.

Simply Wall St also provides a Fair Ratio of 30.72x, which is its view of what Elevance Health's P/E might be given factors such as earnings growth, profit margins, industry, market cap and company specific risks. This Fair Ratio can offer a more tailored yardstick than simple comparisons with peers or industry averages because it adjusts for these business characteristics rather than treating all companies as identical. On this measure, Elevance Health's current P/E of 11.05x sits well below the Fair Ratio of 30.72x, which indicates that the shares appear undervalued on a P/E basis.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Elevance Health Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced as a simple way for you to write the story behind your numbers by linking your view on Elevance Health’s revenue, earnings and margins to a forecast and then to a Fair Value that sits right alongside the live share price on Simply Wall St’s Community page. This Fair Value updates automatically when fresh news or earnings arrive and can help you decide if the gap between Fair Value and price looks wide enough to act, whether you lean closer to a cautious view around a Fair Value near US$297, a more optimistic view closer to US$507, or something in between around US$370 to US$390.

Do you think there's more to the story for Elevance Health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com